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From islets of Langerhans to insulin  
analogs. It’s been almost 100 years  
since the discovery of insulin
ABSTRACT
Until the discovery of insulin, diabetes was a fatal 
disease. The diet was the only form of treatment for 
this disease. Since the discovery of the Langerhans 
Islands, huge progress has been made in the treat-
ment of diabetes. In 1921 due to Banting’s research 
and collaborators, there has been a revolution in the 
treatment of diabetes. A disease that was once incur-
able could be controlled by insulin injections. Today 
insulin is not only a life-saving medicine. After the 
breakthrough discovery of scientists, research was 
conducted to improve insulin. Ultimately, these actions 
led to the creation of insulin analogs to make diabetes 
therapy even more perfect, by reducing the incidence 
of hypoglycemia. (Clin Diabetol 2019; 8, 5: 258–261)
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Introduction
Insulin is an anabolic peptide hormone produced 
and secreted by the beta cells of the pancreas. This 
hormone is involved in the metabolism of carbohy-
drates, fats, and proteins. Moreover, insulin influences 
genes expression and has an antiapoptotic effect. In 
people with diabetes, depending on the type of the 
disease, there is a problem with its production in ap-
propriate amounts or with proper functioning. In 1951, 
researchers and physicians Lawrence and Bornstein 
(United Kingdom) measured blood levels of insulin in 
10 diabetic patients and recorded major differences in 
the results of these measurements. Researchers have 
observed a lack of insulin in young people, while in 
older and obese people, they found significant amounts 
of this hormone in the blood [1]. Modern medicine 
owes the discovery of insulin to many scholars who 
over the course of several decades have conducted 
a number of studies aimed at improving insulin therapy. 
Insulin-dependent diabetes, which for many hundreds 
of years was a fatal disease, has become a disease 
that could be treated, controlled more effectively, and 
reduced the adverse effects of its action on patients. 
Frederick Grant Banting is a scientist recognized as the 
discoverer of insulin. However, before him, there were 
many researchers who explored the topic of diabetes 
and who have gone down in the history of medicine. 
Term ‘insulin’ had been introduced by Jean de Meyer 
(1878–1934) in 1909 [2]. In this, he was followed by 
English physiologist Edward Albert Sharpey-Schafer 
(1850–1935), who in 1913, in lectures at Stanford 
University, he suggested the name ‘insuline’ for a sub-
stance in the islets of Langerhans then unknown [3]. 
Using radioimmunoassay technology, Solomon Berson, 
and Rosalyn Yalow in 1960 developed a method for 
measuring insulin in the blood. They observed that 
some people with diabetes still make their own insu-
lin, and on this basis, they determined the occurrence 
of ‘insulin-dependent’ and ‘non-insulin-dependent’ 
diabetes [4].
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The islets of Langerhans,  
or how did it begin?
The history of insulin therapy begins in 1869. The 
German 22-year-old medical student Paul Langerhans 
(1847–1888), while working on a microscope, identifies 
for the first time a group of cells within the pancreas, 
about which he writes: “(…) small cells of almost perfect 
homogeneous content and of a polygonal form, with 
round nuclei without nucleoli, mostly lying together in 
pairs or small groups” [5]. Langerhans admitted that 
he did not know the function of these special cells. The 
discovery of a student from Berlin did not find interest 
among scholars for many years, until 1893 when Gustav 
Laguesse bent over them. A group of cells was named 
by him ‘Langerhans islands’. The scientist proposed 
that the pancreatic islets may play the endocrine role 
and produce a substance that reduces blood glucose 
levels [6]. The concept of ‘pancreatic diabetes’ was 
introduced in 1877 by Frenchman Etienne Lancereaux 
(1829–1910) [7]. In 1901, pathologist Eugene Lindsay 
Opie (1873–1971) described the occurrence of hyaline 
degeneration within the Langerhans islands in diabetes. 
At the same time, he hypothesized that these changes 
may condition the occurrence of the disease [8]. De-
spite the above-mentioned discoveries, the substance 
produced by the pancreas has not yet been used as 
a drug in people with diabetes. However, the research-
ers attempted to isolate island secretion, which proved 
to be ineffective. The German physician George Ludwig 
Zuelzer (1870–1949) obtained and applied pancreatic 
extract for the first time in 1906. The results of the ex-
periment were promising at first because the sugar was 
reduced or the total disappearance of sugar from the 
urine was observed. However, the preparation caused 
side effects in the form of allergic-toxic reactions and 
hypoglycemia [9]. On 28 May 1912, Zuelzer patented 
his method in the United States. In contrast, Dr. Ernest 
Scott (1877–1966) (University of Chicago) in 1911 and 
Israel Kleiner (1885–1966) (Rockefeller University in 
New York) in 1919, giving an aqueous extract of the 
pancreas to dogs, obtained a temporary reduction of 
glucose level in urine and blood [10, 11]. Romanian 
professor of physiology Nicolas Paulesco (1869–1931) 
(Medical University of Bucharest) in 1916 refined the ac-
quisition of aqueous extract from the pancreas, which 
in diabetic dogs had a normalizing effect on sugar level 
in the blood and urine. In addition, he observed a de-
crease in urea in the blood and urine. In 1921 Paulescu 
published his data in two prominent French journals, 
eight months before the first publication of Banting 
and Best from February 1922 [12]. Unfortunately, the 
work of scientists interrupted the outbreak of World 
War I or the disapproval of university authorities. De-
spite attempts to isolate the substance that reduces 
blood glucose, it has not been able to be used in clini-
cal practice. However, these studies have had a huge 
impact on further work leading to the final isolation of 
insulin and its administration to the patient. By the time 
of significant progress in the treatment of diabetes, 
i.e. the nineteenth and twentieth centuries, it was not 
possible to determine what causes diabetes, and it was 
not known how to treat it. People with diabetes died 
from exhaustion and due to complications. The only 
known treatment at that time was diet.
The breakthrough time has come...
The discovery of insulin by Canadian scientists 
changed the treatment of diabetes completely and 
improved the prognosis of patients. It was a break-
through moment, a milestone in the history of diabetes 
and one of the greatest achievements in medicine. In 
addition to research activities, Frederick Grant Banting 
(1891–1941), a young orthopedic surgeon, lectured for 
medical students. In October 1920, when preparing for 
a lecture on the subject of the pancreas, he found an 
article about pancreatolithiasis. Due to the mechanical 
blockade of pancreatic ducts, the disease caused atro-
phy of cells secreting digestive enzymes, but the func-
tion of the islets of Langerhans remained unchanged. 
Mering and Minkowski, in their experiments, ligated 
pancreatic ducts in dogs, which caused similar results. 
This prompted Banting to repeat the experiment. The 
dogs examined had the pancreas removed or ligated 
pancreatic ducts. The pancreas with ligated ducts 
underwent the extraction process and the solution 
he obtained was injected into diabetic dogs. Banting 
observed a short-term reduction in the glucose level in 
the blood and urine, which resulted from contamina-
tion of the extract by digestive enzymes. In addition, 
adverse reactions at the injection site in the form of 
abscesses were observed due to the administration of 
a poorly purified pancreatic extract. Banting’s colleague 
suggested re-conducting experiments in a specialized 
laboratory at the University of Toronto under the super-
vision of medical professor John James Richard Macleod 
(1876–1935), a well-known Scottish physiologist and 
diabetes specialist from Aberdeen. Macleod was one 
of the greatest specialists in the field of carbohydrate 
metabolism. In the spring of 1921, Macleod agreed to 
make the laboratory and experimental animals avail-
able to Banting and offered him the assistance of two 
medical students, Charles Herber Best (1899–1978) 
and Edward Clark Noble. Best became Banting’s clos-
est associate, and their work in the Toronto laboratory 
resulted in exceptional results. The extract obtained 
by the researchers, which they called the isletine, was 
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subjected to purification at the request of Professor 
Macleod. This task belonged to the Canadian bio-
chemist James Bertram Collip (1892–1965). Obtaining 
a maximum purified and minimally toxic pancreatic 
extract allowed for its clinical use and subcutaneous 
administration to a diabetic patient. This treatment 
saved the life of 14 year-old Leonard Thompson, a na-
tive of Toronto. The boy had diabetes for three years 
and his body weight was only 30 kilograms. Leonard 
was in a diabetic coma, in which he collapsed and woke 
up alternately. His father agreed to give his son a newly 
discovered drug, previously tested on animals. The 
first injection of insulin occurred on 11 January 1922. 
However, its first clinical application did not bring about 
a spectacular effect, because only a 25% reduction in 
glucose was obtained. In addition, glucose and ketone 
bodies remained in the urine of the patient. An abscess 
appeared at the injection site, and the patient devel-
oped a severe allergic reaction to the newly discovered 
drug. Insulin therapy was considered ineffective, but 
the researchers decided to improve the effectiveness 
of the discovered drug. Cooperation with Connaught 
Laboratories allowed for achievement the more purified 
insulin. On 23 January 1922, the obtained preparation 
was given to the boy in several injections a day. Then the 
expected effect was observed — the glucose concentra-
tion dropped significantly in the blood and urine. Also, 
the symptoms of diabetic acidosis have disappeared, 
which was accompanied by the complete disappear-
ance of ketone bodies in the urine. The boy died at the 
age of 27, but the cause of his death was not diabetes 
and its complications, but pneumonia. Researchers 
continued testing the extract and in February 1922 
qualified six people for treatment, but in these cases, 
the treatment was successful [13–19]. For the first time, 
the researchers announced the results of their work in 
May 1922 during the meeting of the Association of 
American Physicians. Discoverers were represented by 
Macleod, who talked about the discovery and use of 
insulin. Soon the production of insulin on a large scale 
began. The first company that chose to do this was 
the Connaught Laboratories in Indianapolis, but the 
insulin they produced was ineffective clinically. Another 
company that took up the challenge was Eli Lilly from 
Toronto. They were stronger than their predecessors 
because production was very large, but also their 
activity proved to be ineffective. In November 1922, 
the cause of the lack of efficacy of insulin produced 
by Lilly was discovered. Their chief chemist George 
Walden found that insulin was reduced in purity due to 
precipitation at the improper pH [20]. However, failures 
in the production process were not the only obstacles. 
These were eliminated, while issues such as production 
standardization or patent law remained to be resolved. 
The interest in insulin has reached large proportions and 
its production has been taken up by numerous scientific 
and commercial centers. One of them was a non-profit 
body, the Nordisk Insulin Laboratory, which is currently 
one of the leading insulin companies. This undertaking 
was initiated in 1923 by an eminent physiologist Nobel 
laureate for research on metabolism and physical ef-
fort, August Krogh from the University of Copenhagen, 
whose wife was diabetic. During a meeting with Bant-
ing and Macleod, he got the knowledge of insulin and 
received authorization from the University of Toronto to 
bring insulin to Scandinavia [21]. During the work on 
the discovery of insulin, there were conflicts between 
the members of the research team. The source of the 
conflict was the first public report on the results of the 
experimental treatment of diabetes in animals with 
a partially purified solution of insulin. Macleod wanted 
to be recognized as a leading researcher, while Bant-
ing’s position in the medical world was not strong 
enough. However, both scientists were noticed and 
honored. In 1923, Banting and MacLeod received 
the Nobel Prize in medicine and physiology. However, 
they did not forget about their closest collaborators, 
without which we would not use insulin today. Bant-
ing donated half of the award to Charles Herbert Best, 
while MacLeod shared the prize with James Bertram 
Collip. Never before has a scientist received the Nobel 
Prize in such a short time after the discovery.
From NPH insulin to analogs
Insulin derived from animals has been used to treat 
diabetes for many years. Despite the effectiveness and 
increase in survival, insulin was not devoid of imperfec-
tions due to the occurrence of allergic reactions in many 
patients. Research has been carried out on improving 
insulin. One of the shortcomings of insulin therapy at 
the time was the necessity of administering the drug 
in several injections a day. The researchers sought to 
create long-acting insulin. The year 1936 is the time 
when the long-acting insulin, containing an admixture 
of protein — protamine, was first developed. This was 
accomplished by the assistant of August Krogh, Hans 
Christian Hagedorn. The preparation was named as 
insulin with a prolonged action type NPH (neutral pro-
tamine Hagedorn) [22]. At the same time, in Toronto 
Scott and Fisher further prolonged the effect of insulin 
by adding zinc [23]. These findings led to the launch 
of longer-acting animal insulins. The world of science 
got to know insulin more and more. In 1955, a scientist 
from the University of Cambridge, Frederick Sanger 
determined the amino acid sequence of insulin, for 
which he received the Nobel Prize [24]. The year 1958 
Aleksandra Cieluch et al., History of the discovery of insulin
261
is also a breakthrough in genetic engineering because 
insulin as the first protein was successfully synthesized 
chemically as the first drug produced by genetic engi-
neering methods. In 1959, Paul Lacy confirmed with 
immunohistochemistry that the cell responsible for the 
production of insulin is the b cell [25]. In 1969, Dorothy 
Hodgkin of the University of Cambridge determined the 
spatial structure of the insulin molecule, for which she 
was awarded the Nobel Prize.
The era of human insulins and their analogs have 
come. In 1978, David Goeddel, Ph.D., and colleagues 
at Genentech prepared the first recombinant human 
insulin by utilizing and combining the insulin A- and 
B-chains expressed in Escherichia coli. Afterward, Ge-
nentech and Lilly signed an agreement to commercialize 
human insulin produced by recombinant DNA. The first 
recombinant insulins launched in 1982 were Humulin R 
(short-acting) and N (NPH, intermediate-acting) [26]. To 
make diabetes therapy even more perfect, by reducing 
the incidence of hypoglycemia, insulin preparations 
were sought that mimicked the physiological secretion 
of insulin. The change in pharmacokinetics due to the 
modification of the amino acid site in insulin led to 
the formation of insulin analogs. These insulins were 
characterized by faster absorption and shorter dura-
tion of action. The first rapid-acting analog of insulin 
introduced to the market in 1996 was lispro. In 2000 
and 2005, aspart and glulisine were introduced respec-
tively. In contrast, long-acting insulin analogs were 
approved in 2000 (glargine) and 2005 (detemir). The 
next generation of insulin analogs are ultralong-acting 
insulin analogs glargine U300 and degludec (2015).
Conclusions
Over the decades, there has been undeniable pro-
gress in the treatment of diabetes. The disease, once 
considered deadly, become a chronic disease. However, 
complications of diabetes continue to be an important 
problem. Insulin has become a drug of opportunity for 
people with diabetes, and its continuous refinements 
have made metabolic control of the disease often 
achieved perfectly.
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